Aakash Desai, Associate Director, Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“DICIPLE Phase III: 4-Year Outcomes of 6-Month vs Continuation Nivolumab+Ipilimumab in Advanced NSCLC
Key Findings:
- PFS: 18.7 months (continuation) vs Not Reached (6-month)
- OS: 55.5 months vs Not Reached
- 18-month OS: 80.6% vs 93.8%
- Grade 3-5 irAEs: 54.3% → 23.5% (57% reduction)
- QoL deterioration: 15.5 months vs Not Reached (HR=0.36)
Clinical Impact: Stopping at 6 months in controlled mNSCLC showed no survival harm, dramatically reduced toxicity, and delayed QoL deterioration.”
Other articles featuring Aakash Desai.